Patterns of Molecular Response to and Relapse After Combination of Sorafenib, Idarubicin, and Cytarabine in Patients with Newly Diagnosed FLT3-Mutant Acute Myeloid Leukemia (AML)

被引：0

作者：

Al-Kali, Aref ^{[1
]}

Jones, Dan ^{[1
]}

Cortes, Jorge ^{[1
]}

Faderl, Stefan ^{[1
]}

Ao, Xue ^{[1
]}

Garcia-Manero, Guillermo ^{[1
]}

Borthakur, Gautam ^{[1
]}

Konopleva, Marina ^{[1
]}

Brandt, Mark ^{[1
]}

Andreeff, Michael ^{[1
]}

Kantarjian, Hagop ^{[1
]}

Ravandi, Farhad ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

BLOOD | 2009年 / 114卷 / 22期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：820 / 821

页数：2

共 50 条

[21] Low Relapse Rate in Younger Patients ≤ 60 Years Old with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML) Treated with Crenolanib and Cytarabine/Anthracycline Chemotherapy
Wang, Eunice S.
Tallman, Martin S.
Stone, Richard M.
Walter, Roland B.
Karanes, Chatchada
Jain, Vinay
Collins, Robert H.
BLOOD, 2017, 130
[22] Crenolanib, a Type I FLT3 TKI, Can be Safely Combined with Cytarabine and Anthracycline Induction Chemotherapy and Results in High Response Rates in Patients with Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia (AML)
Wang, Eunice S.
Stone, Richard M.
Tallman, Martin S.
Walter, Roland B.
Eckardt, John R.
Collins, Robert
BLOOD, 2016, 128 (22)
[23] Extensive Squamous Cell Carcinoma of the Skin Related to Use of Sorafenib for Treatment of FLT3-Mutant Acute Myeloid Leukemia
Fathi, Amir T.
Lin, William M.
Durazzo, Tyler
Piris, Adriano
Sadrzadeh, Hossein
Bernardo, Lindsay
Borger, Darrel R.
McAfee, Steven L.
Kroshinsky, Daniela
Chen, Yi-Bin
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (08) : E70 - E72
[24] Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia
Nazha, Aziz
Kantarjian, Hagop
Ravandi, Farhad
Huang, Xuelin
Choi, Sangbum
Garcia-Manero, Guillermo
Jabbour, Elias
Borthakur, Gautam
Kadia, Tapan
Konopleva, Marina
Cortes, Jorge
Ferrajoli, Alessandra
Kornblau, Steve
Daver, Naval
Pemmaraju, Naveen
Andreeff, Michael
Estrov, Zeev
Du, Min
Brandt, Mark
Faderl, Stefan
AMERICAN JOURNAL OF HEMATOLOGY, 2013, 88 (11) : 961 - 966
[25] A Randomized Phase 2 Study of Idarubicin and Cytarabine With Clofarabine or Fludarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia
Jabbour, Elias
Short, Nicholas J.
Ravandi, Farhad
Huang, Xuelin
Xiao, Lianchun
Garcia-Manero, Guillermo
Plunkett, William
Gandhi, Varsha
Sasaki, Koji
Pemmaraju, Naveen
Daver, Naval G.
Borthakur, Gautam
Jain, Nitin
Konopleva, Marina
Estrov, Zeev
Kadia, Tapan M.
Wierda, William G.
DiNardo, Courtney D.
Brandt, Mark
O'Brien, Susan M.
Cortes, Jorge E.
Kantarjian, Hagop
CANCER, 2017, 123 (22) : 4430 - 4439
[26] Longer Follow-Up Of The Combination Of Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy For Patients Younger Than 61 Years With Newly Diagnosed Acute Myeloid Leukemia (AML)
Nazha, Aziz
Kantarjian, Hagop M.
Ravandi, Farhad
Huang Xuelin
Choi, Sangbum
Garcia-Manero, Guillermo
Jabbour, Elias
Borthakur, Gautarn
Kadia, Tapan M.
Konopleva, Marina
Cortes, Jorge E.
Ferrajoli, Alessandra
Kornblau, Steven M.
Andreeff, Michael
Du, Min
Brandt, Mark
Faderl, Stefan H.
BLOOD, 2013, 122 (21)
[27] Interim results of a phase I/II randomized study of clofarabine, idarubicin, and cytarabine (CIA) versus fludarabine, idarubicin, and cytarabine (FIA) for newly diagnosed or relapsed patients (pts) with acute myeloid leukemia (AML).
Mathisen, Michael
Kantarjian, Hagop
Faderl, Stefan
Garcia-Manero, Guillermo
Ravandi, Farhad
Kadia, Tapan M.
Daver, Naval Guastad
O'Brien, Susan Mary
Dorkhom, Stephan Joseph
Pierce, Sherry
Lira, Cynthia
Cortes, Jorge E.
Jabbour, Elias
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[28] Phase II Study of Cladribine, Idarubicin, Cytarabine (CLIA) Plus Gilteritinib in Patients with FLT3 Mutated Acute Myeloid Leukemia (AML)
Abuasab, Tareq
Kantarjian, Hagop
Garcia-Manero, Guillermo
Montalban-Bravo, Guillermo
Alvarado, Yesid
Yilmaz, Musa
Pemmaraju, Naveen
Chien, Kelly S.
Mohamed, Shehab Fareed
Daver, Naval
Kornblau, Steven M.
Burger, Jan A.
Jain, Nitin
Islam, Rubiul
DiNardo, Courtney D.
Borthakur, Gautam
Ravandi, Farhad
Kadia, Tapan M.
BLOOD, 2021, 138
[29] Phase II study of cladribine, idarubicin, cytarabine (CLIA) plus gilteritinib in patients (pts) with FLT3 mutated acute myeloid leukemia (AML).
Abuasab, Tareq
Kantarjian, Hagop M.
Garcia-Manero, Guillermo
Bravo, Guillermo Montalban
Valero, Yesid Alvarado
Daver, Naval Guastad
Yilmaz, Musa
Pemmaraju, Naveen
Chien, Kelly Sharon
Kornblau, Steven Mitchell
Burger, Jan Andreas
Jain, Nitin
Islam, Rabiul
Dinardo, Courtney Denton
Borthakur, Gautam
Jabbour, Elias
Ravandi, Farhad
Kadia, Tapan M.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[30] Tolerability and Efficacy of Crenolanib and Cytarabine/Anthracycline Chemotherapy in Older Patients (Aged 61 to 75) with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML)
Wang, Eunice S.
Griffiths, Elizabeth A.
Walter, Roland B.
Tallman, Martin S.
Goldberg, Aaron D.
Messahel, Boo
Stone, Richard M.
BLOOD, 2019, 134

← 1 2 3 4 5 →